文献速递肿瘤 PET/CT

68Ga-NOTA-RM26 PET/CT 在乳腺癌评估中的初步前瞻性研究

68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study.
PubMed 文献 · Clin Nucl Med · 2018-01-01

这项前瞻性先导研究纳入35例经乳腺X线或超声怀疑乳腺癌的女性,术前1周内静脉注射68Ga-NOTA-RM26(1.85 MBq/kg)后30分钟行PET/CT,分析摄取值与病理及免疫组化结果的相关性。34例确诊乳腺癌中,雌激素受体(ER)阳性者SUVmax为4.97±1.89,显著高于ER阴性者的2.78±0.65(P<0.001)。排除月经分泌期患者后,鉴别乳腺癌与乳腺组织的敏感性、特异性和准确性分别从85.3%、86.8%、86.1%提高至100%、90.9%、95.5%。

要点

  • 68Ga-NOTA-RM26摄取的阳性率与ER表达(P=0.006)和月经状态(P=0.019)相关。
  • ER阳性乳腺癌SUVmax为4.97±1.89,显著高于ER阴性的2.78±0.65(P<0.001)。
  • 分泌期正常乳腺组织SUVmax为2.27±0.71,高于非分泌期的1.59±0.49(P=0.017)和绝经后的1.43±0.44(P=0.002)。

核心结论

  • 这项先导研究提示,68Ga-NOTA-RM26 PET/CT对乳腺癌的诊断准确性可能与患者ER表达和月经状态相关。
  • 作者认为,为避免正常乳腺组织的生理性摄取,最好避免在月经分泌期进行该检查。

研究设计与样本

  • 前瞻性先导研究,纳入35例经乳腺X线或超声怀疑乳腺癌并签署知情同意书的女性。
  • 受试者在手术前1周内接受静脉注射68Ga-NOTA-RM26(剂量1.85 MBq/kg,即0.05 mCi/kg)后30分钟行PET/CT扫描。
  • 将68Ga-NOTA-RM26摄取值与病理及免疫组化结果进行相关性分析。

主要发现

  • 68Ga-NOTA-RM26阳性与雌激素受体(ER)表达相关(P=0.006),与月经状态相关(P=0.019)。
  • 34例确诊乳腺癌患者中,ER阳性乳腺癌的SUVmax为4.97±1.89,显著高于ER阴性乳腺癌的2.78±0.65(P<0.001)。
  • 68Ga-NOTA-RM26在正常乳腺组织中也有摄取,月经周期分泌期患者的SUVmax为2.27±0.71,显著高于非分泌期患者的1.59±0.49(P=0.017)和绝经后患者的1.43±0.44(P=0.002)。
  • 排除分泌期患者后,鉴别乳腺癌与乳腺组织的敏感性、特异性和准确性分别从85.3%、86.8%、86.1%提高至100%、90.9%、95.5%。

临床怎么用

  • 作者认为,为避免正常乳腺组织的生理性摄取,最好避免在月经分泌期进行该检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This prospective pilot study investigated the value of Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor, in evaluation of breast cancer. METHODS: Thirty-five women in suspicion of breast cancer based on mammography or ultrasonography were recruited with informed consent. They underwent PET/CT scans 30 minutes after intravenous injection of Ga-NOTA-RM26 in a dose of 1.85 MBq (0.05 mCi) per kilogram body weight within 1 week before surgery. The Ga-NOTA-RM26 uptake was correlated with the pathological and immunohistochemical findings. RESULTS: Ga-NOTA-RM26 positivity was found correlated with estrogen receptor (ER) expression (P = 0.006) and menstrual status (P = 0.019). In 34 patients diagnosed with breast cancer, the SUVmax was found significantly higher in the ER-positive breast cancer (4.97 ± 1.89) than in the ER-negative breast cancer (2.78 ± 0.65, P < 0.001). Ga-NOTA-RM26 was also found accumulated in normal breast tissue, with the SUVmax significantly higher in patients at the secretory phase of menstrual cycle (2.27 ± 0.71) than in those at the nonsecretory phase (1.59 ± 0.49, P = 0.017) and postmenopause (1.43 ± 0.44, P = 0.002). If the secretory phase patients were excluded, the sensitivity, specificity, and accuracy for differentiation of breast cancer from breast tissue increased from 85.3%, 86.8%, and 86.1% to 100%, 90.9%, and 95.5%, respectively. CONCLUSIONS: This pilot study indicates that the diagnostic accuracy of Ga-NOTA-RM26 PET/CT in breast cancer may correlate with ER expression and menstrual status of the patient. It may be better to avoid performing this examination during the menstrual secretory phase to reduce physiological uptake in normal breast tissue.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zang J, Mao F, Wang H, et al. 68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study. Clin Nucl Med. 2018. PMID: 30036253. doi:10.1097/RLU.0000000000002209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。